Neuraxpharm Group has announced an expansion of its operations in the Swiss pharmaceutical market.
After having laid the groundwork for its Swiss business in the recent past, the company has reinforced its position in the market with the appointment of Jörg Gärtner as Country Manager for Switzerland.
Neuraxpharm aims to tap into the Swiss market’s commercial potential through its product offerings in CNS medication. In the region, the company will provide access to suitable products out of its extensive portfolio, including the recently acquired Buccolam for emergency treatment of children and adolescents with epilepsy. It entered the market through the acquisition of S.T.U., a distributor of CBD consumer products, in 2019. Within the next months, Neuraxpharm plans to launch its medical cannabis portfolio to answer the increasing demand in the booming market.
Throughout more than 25 years in the pharmaceutical industry, Gärtner has gained knowledge of different countries, companies, and various therapeutic indications. He has a strong track record in launching products in competitive markets such as Germany, Austria and Switzerland, the company says. At Neuraxpharm, he will leverage this experience with the aim of expanding the company’s market share in Switzerland.
Gärtner said: "I am excited to join Neuraxpharm as Country Manager. Neuraxpharm is in the perfect position to successfully expand in the Swiss market – in CNS products and beyond. I look forward to working with my new team and to making available my expertise both in the pharmaceutical industry as well as in Switzerland."
Dr Jörg-Thomas Dierks, CEO of Neuraxpharm, said: "The Swiss market is of high strategic relevance for Neuraxpharm. After entering the market relatively recently through the acquisition of S.T.U. and its CBD portfolio, we are now very confident that with Jörg Gärtner we will successfully take our Swiss business to the next level. With his vast experience and entrepreneurial mindset, Jörg is best suited to leverage growth opportunities in the CNS and medical cannabis markets.”
